Sapna Salar
Sapna Salar has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Dinesh Kumar Yadav
Department of Pharmacognosy, SGT College of Pharmacy, SGT University, Gurugram Haryana, 122505, India
2 shared publications - Santosh Kumar
Department of Botany, Maharaja Bijli Pasi Government Post Graduate College, Ashiyana, Lucknow, 226012, India
2 shared publications - Anjali Singh1 shared publication
Mahaveer Singh
Pharmacy Academy, IFTM University, Moradabad, 244102, Uttar Pradesh, India
1 shared publication- Manju Singh
Department of Pharmaceutics, Dr. KN Modi Institute of Pharmaceutical Education and Research, Kapda Mill, opposite SBI Main Branch, Modinagar, Uttar Pradesh 201204 India
1 shared publication Mansi Aggarwal
Department of Pharmacology, IIMT College of Medical Sciences, IIMT University, Ganga Nagar, 250001, Meerut,Uttar Pradesh, India
1 shared publication
Latest Publications
- Open Access
- 2 September 2026
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 6 (4) , 506-515
High-Throughput Chromatographic and Spectroscopic Profiling for Reliable Differentiation of Hyoscyamus niger and Cleome viscosa L.
Quality evaluation of herbal medicines is essential to ensure their safety, efficacy, and consistency. The present study focused on the quality control and authentication of Hyoscyamus niger (henbane) and its adulterant Cleome viscosa L. using modern analytical techniques. Both plants possess significant medicinal value but are often adulterated, affecting therapeutic reliability. The study aimed to differentiate and authenticate H. niger and C. viscosa through macro- and microscopic characterization, followed by chemical profiling using High-Performance Thin-Layer Chromatography (HPTLC) and High-Performance Liquid Chromatography coupled with Mass Spectroscopy (HPLC–MS). These advanced tools enabled rapid, simultaneous analysis of multiple phytoconstituents, facilitating efficient quality assessment. The results revealed distinct differences in macro- and microscopic features between the two species. Chemical profiling identified characteristic marker compounds specific to each plant, allowing clear discrimination between authentic and adulterated samples. Quantitative estimation of total alkaloid content showed a notable variation, with H. niger containing 0.1737 ± 0.0023% and C. viscosa 0.0441 ± 0.0018% (w/w). Overall, the findings highlight the effectiveness of combining high-throughput screening with advanced analytical approaches for the authentication of medicinal plants. This integrated strategy strengthens quality control measures, ensuring the authenticity, potency, and safety of herbal formulations, and supports the development of robust quality assurance protocols in the herbal industry.
- 2 September 2026
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 6 (4) , 506-515
Open AccessHigh-Throughput Chromatographic and Spectroscopic Profiling for Reliable Differentiation of Hyoscyamus niger and Cleome viscosa L.
Quality evaluation of herbal medicines is essential to ensure their safety, efficacy, and consistency. The present study focused on the quality control and authentication of Hyoscyamus niger (henbane) and its adulterant Cleome viscosa L. using modern analytical techniques. Both plants possess significant medicinal value but are often adulterated, affecting therapeutic reliability. The study aimed to differentiate and authenticate H. niger and C. viscosa through macro- and microscopic characterization, followed by chemical profiling using High-Performance Thin-Layer Chromatography (HPTLC) and High-Performance Liquid Chromatography coupled with Mass Spectroscopy (HPLC–MS). These advanced tools enabled rapid, simultaneous analysis of multiple phytoconstituents, facilitating efficient quality assessment. The results revealed distinct differences in macro- and microscopic features between the two species. Chemical profiling identified characteristic marker compounds specific to each plant, allowing clear discrimination between authentic and adulterated samples. Quantitative estimation of total alkaloid content showed a notable variation, with H. niger containing 0.1737 ± 0.0023% and C. viscosa 0.0441 ± 0.0018% (w/w). Overall, the findings highlight the effectiveness of combining high-throughput screening with advanced analytical approaches for the authentication of medicinal plants. This integrated strategy strengthens quality control measures, ensuring the authenticity, potency, and safety of herbal formulations, and supports the development of robust quality assurance protocols in the herbal industry.
- 8 April 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 22
Role of Paclitaxel in Endometriosis: An Insight into its Safety Profile and Biomolecular Approaches
The chemotherapeutic agent paclitaxel is being presented as a promising antiendometriotic treatment. Endometriosis is a common gynecological disorder that leads to chronic peritoneal pain and infertility. It is characterized by the presence of endometrial tissue outside the uterus. In this review, the anti-endometriotic features of paclitaxel are analyzed and discussed from both pharmacological and biomolecular perspectives. Paclitaxel acts pharmacologically as a microtubule- stabilizing agent, interfering with the cell cycle and preventing the formation of new cells. It also exhibits anti-angiogenic activity, inhibiting the growth of new blood vessels and thereby reducing the vascularization of endometriotic lesions. Moreover, paclitaxel modulates immune responses, inducing an anti-inflammatory environment during endometriosis. At the biomolecular level, paclitaxel affects important signaling pathways involved in endometriotic pathogenesis. It acts on molecules such as transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), nuclear factor-kappa B (NF-κB), and matrix metalloproteinases (MMPs), which play roles in inflammation, neovascularization, and tissue remodeling associated with endometriosis. This review provides detailed insights into the research conducted on paclitaxel, including its safety and efficacy as a treatment for endometriosis. It also examines different methods of administration, dosage schedules, and combination strategies aimed at enhancing its therapeutic effects. In conclusion, paclitaxel represents a potential therapeutic strategy for endometriosis by acting not only through its pharmacological properties but also through its biomolecular effects on the disease. Additional investigations are needed to elucidate its mechanisms of action, determine optimal treatment schedules, and explore new combination therapies to improve outcomes in patients with endometriosis.
- 8 April 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 22
Role of Paclitaxel in Endometriosis: An Insight into its Safety Profile and Biomolecular Approaches
The chemotherapeutic agent paclitaxel is being presented as a promising antiendometriotic treatment. Endometriosis is a common gynecological disorder that leads to chronic peritoneal pain and infertility. It is characterized by the presence of endometrial tissue outside the uterus. In this review, the anti-endometriotic features of paclitaxel are analyzed and discussed from both pharmacological and biomolecular perspectives. Paclitaxel acts pharmacologically as a microtubule- stabilizing agent, interfering with the cell cycle and preventing the formation of new cells. It also exhibits anti-angiogenic activity, inhibiting the growth of new blood vessels and thereby reducing the vascularization of endometriotic lesions. Moreover, paclitaxel modulates immune responses, inducing an anti-inflammatory environment during endometriosis. At the biomolecular level, paclitaxel affects important signaling pathways involved in endometriotic pathogenesis. It acts on molecules such as transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), nuclear factor-kappa B (NF-κB), and matrix metalloproteinases (MMPs), which play roles in inflammation, neovascularization, and tissue remodeling associated with endometriosis. This review provides detailed insights into the research conducted on paclitaxel, including its safety and efficacy as a treatment for endometriosis. It also examines different methods of administration, dosage schedules, and combination strategies aimed at enhancing its therapeutic effects. In conclusion, paclitaxel represents a potential therapeutic strategy for endometriosis by acting not only through its pharmacological properties but also through its biomolecular effects on the disease. Additional investigations are needed to elucidate its mechanisms of action, determine optimal treatment schedules, and explore new combination therapies to improve outcomes in patients with endometriosis.